Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 28 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

14%

4 trials in Phase 3/4

Results Transparency

10%

1 of 10 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (7)
P 2 (7)
P 3 (3)
P 4 (1)

Trial Status

Completed10
Recruiting6
Unknown6
Not Yet Recruiting3
Enrolling By Invitation2
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (28)

Showing 20 of 20 trials
NCT07728825Phase 4CompletedPrimary

Intralesional Bleomycin Sclerotherapy for Low-Flow Vascular Malformations of the Head and Neck

NCT07720570Enrolling By InvitationPrimary

Bleomycin Electrosclerotherapy (BEST) for Slow-flow Vascular Malformations

NCT06789913Phase 2Recruiting

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

NCT06189092RecruitingPrimary

Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational Study

NCT07579962Phase 2Not Yet RecruitingPrimary

Treatment of Low-flow Vascular Malformations With Bleomycin Electrosclerotherapy (BEST)

NCT05983159Phase 2Recruiting

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

NCT07477548Phase 2Not Yet RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

NCT05563831Completed

National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

NCT03972592Phase 2CompletedPrimary

Topical Sirolimus in Cutaneous Lymphatic Malformations

NCT07404670Not ApplicableNot Yet Recruiting

Microwave Ablation for Treatment of Vascular Malformations: Efficacy and Safety

NCT07037238Phase 2RecruitingPrimary

An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations

NCT04104464RecruitingPrimary

Patient Reported Outcomes for Vascular Malformations EmbolizatioN (PROVEN)

NCT05418816Not ApplicableActive Not Recruiting

SelfWrap-Assisted Arteriovenous Fistulas

NCT06399367Enrolling By Invitation

Investigation of Lipedema, Lymphedema and Vascular Malformations by Multispectral Optoacoustic Tomography (MSOT)

NCT06160739Unknown

Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations

NCT02384122Phase 3Completed

Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias

NCT02638389Phase 3RecruitingPrimary

Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care

NCT05494710Not ApplicableUnknownPrimary

Bleomycin Electrosclerotherapy Treatment of Vascular Malformations: A Feasibility Study

NCT04836884Not ApplicableCompletedPrimary

Vascular Anomaly Pathology and Genomics Biopsy Study

NCT02561182Completed

Bone Health in Patients With Overgrowth

Scroll to load more

Research Network

Activity Timeline